Showing results (201-210 of 238) with videos related to

Sort By:
Pageof 24
Trials|March 28, 2007
Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trialEusebio V Macete, Jahit Sacarlal, John J Aponte, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer GroupAristotelis Bamias, Konstantinos Koutsoukos, Nikos Gavalas, et al.
World Journal of Urology|July 11, 2016
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patientsMichalis Liontos, Eleni-Andriana Trigka, Penelope Korkolopoulou, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)Steven M Yip, Jose M Ruiz Morales, Frede Donskov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 27, 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I NonseminomaStefanie Fischer, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
The Lancet. Infectious Diseases|March 23, 2020
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trialMilagritos D Tapia, Samba O Sow, Khardiata D Mbaye, et al.
Plos One|May 12, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African AdultsGloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, et al.
Frontiers in Immunology|May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccinesCassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
Blood|May 13, 2004
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialJeffrey McCullough, David H Vesole, Richard J Benjamin, et al.
Pageof 24